Format

Send to

Choose Destination
See comment in PubMed Commons below
Sci Rep. 2015 Nov 26;5:17258. doi: 10.1038/srep17258.

The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines.

Author information

  • 1MRC Centre for Regenerative Medicine, Institute for Stem Cell Research, School of Biological Sciences, The University of Edinburgh, UK.
  • 2Department of Reproductive Medicine, St. Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
  • 3Roslin Cells Limited, Nine Edinburgh BioQuarter, Edinburgh, UK.
  • 4Centre for Clinical Brain Sciences and MRC Centre for Regenerative Medicine, The University of Edinburgh, UK.
  • 5Stem Cell Laboratories, Guy's Assisted Conception Unit, Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • 6Centre for Stem Cell Biology, Department of Biomedical Science, The University of Sheffield, Sheffield, UK.
  • 7Faculty of Life Sciences, The University of Manchester, Manchester, UK.

Abstract

The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.

PMID:
26607962
PMCID:
PMC4660465
DOI:
10.1038/srep17258
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center